Ieq Capital LLC Grows Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Ieq Capital LLC boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 1,425.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 126,710 shares of the company's stock after acquiring an additional 118,404 shares during the quarter. Ieq Capital LLC owned about 0.10% of Apellis Pharmaceuticals worth $4,043,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Wolverine Asset Management LLC purchased a new position in Apellis Pharmaceuticals in the third quarter worth $27,000. True Wealth Design LLC purchased a new position in shares of Apellis Pharmaceuticals in the third quarter valued at $27,000. Capital Performance Advisors LLP purchased a new position in shares of Apellis Pharmaceuticals in the third quarter valued at $56,000. KBC Group NV increased its position in shares of Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company's stock valued at $76,000 after buying an additional 679 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company's stock valued at $130,000 after buying an additional 781 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on APLS. Wells Fargo & Company dropped their price target on Apellis Pharmaceuticals from $43.00 to $30.00 and set an "equal weight" rating for the company in a research report on Wednesday, November 6th. Citigroup dropped their price target on Apellis Pharmaceuticals from $63.00 to $51.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group cut Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and set a $36.00 price target for the company. in a research report on Tuesday, December 17th. Bank of America dropped their price target on Apellis Pharmaceuticals from $61.00 to $47.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Finally, Scotiabank dropped their price target on Apellis Pharmaceuticals from $35.00 to $30.00 and set a "sector perform" rating for the company in a research report on Wednesday, November 6th. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $46.71.

Insiders Place Their Bets

In other news, CEO Cedric Francois sold 2,824 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total value of $83,364.48. Following the transaction, the chief executive officer now directly owns 415,695 shares of the company's stock, valued at $12,271,316.40. The trade was a 0.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Caroline Baumal sold 2,816 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $33.81, for a total value of $95,208.96. Following the completion of the transaction, the insider now directly owns 55,560 shares in the company, valued at $1,878,483.60. This represents a 4.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 60,365 shares of company stock valued at $1,810,479. Insiders own 6.80% of the company's stock.

Apellis Pharmaceuticals Stock Down 2.9 %

Shares of NASDAQ:APLS opened at $27.52 on Friday. The stock's 50-day moving average price is $30.61 and its two-hundred day moving average price is $31.87. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 12-month low of $24.34 and a 12-month high of $71.90. The firm has a market cap of $3.42 billion, a price-to-earnings ratio of -13.56 and a beta of 0.96.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.